Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$278.26
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 5, 2026 | $2.72 | $3.02 | Beat +11.0% | $-0.03 | $976.1M | $1B | +2.4% | 1D Pre+1.4% | On-Day+11.4% | 1D Post+1.8% |
Q ended Mar 31, 2026 Reported May 7, 2026 | $1.95 | $2.06 | Beat +5.6% | $-0.30 | $977.44M | $995.83M | +1.9% | 1D Pre-2.0% | On-Day-0.0% | 1D Post-2.2% |
Q ended Dec 31, 2025 Reported Feb 18, 2026 | $2.33 | $2.39 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $986.98M |
| $994.23M |
| +0.7% |
| 1D Pre-1.7% |
| On-Day-0.3% |
| 1D Post+3.9% |
Q ended Sep 30, 2025 Reported Nov 5, 2025 | $2.32 | $2.43 | Beat +4.7% | — | $990.79M | $1B | +0.9% | 1D Pre-0.6% | On-Day-5.7% | 1D Post+1.9% |